Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
← catalyst calendarSponsored by Evommune, Inc. (industry) · EVMN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
71actual
Sites
12
Countries
Australia, New Zealand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-13 | actual | When the study began enrolling |
| Primary completion | 2025-11-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-17 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis (AD)
- Eczema
- Eczema Atopic Dermatitis
Interventions
- Biological: EVO301
- Biological: Placebo
Primary outcome
what the primary-completion date above is the date OFEczema Area and Severity Index (EASI)
measured 12 weeks
Permalink · EVMN's whole pipeline · Catalyst calendar · Every registered study · What changed